Saturday 17 October 2026
Export PPCB’s income statement to Excel — free account
Propanc Biopharma Inc
PPCB Healthcare Biotechnology
In the quarter to June 2026, EPS fell 99.6%, free cash flow fell 1,637.4% and total debt fell 21.4%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow PPCB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (169.85%) | (138.20%) | (2,129.18%) | (1,236.83%) |
+8 more TTM periods Free account |
|
| (122.15%) | (104.68%) | (882.16%) | (702.98%) | ||
ROIC |
(125.86%) | (116.59%) | (390.17%) | (269.80%) | |
Return on Tangible Assets |
(381.25%) | (405.99%) | (1,639.23%) | (1,220.89%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(5.06) | (4.66) | (5.87) | (4.30) | |
Free Cash Flow |
(5.69) | (4.18) | (3.13) | (2.12) | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(53.18%) | (38.91%) | (27.13%) | (13.71%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(42.23) | (27.95) | (90.03) | (78.75) | |
Operating CF/Net income |
0.29 | 0.22 | 0.05 | 0.03 | |
Depreciation/Fixed assets |
0.26 | 0.17 | 0.11 | 0.13 | |
Capex/Depreciation |
(4.90) | (7.00) | (15.40) | (48.67) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.06) | (4.65) | (5.85) | (4.27) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Oct 2026